GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now? Muzurovic E, Yumuk VD, Rizzo M. J Diabetes Complications 2023;37:108647.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Muzurovic E, Yumuk VD, Rizzo M. GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now? J Diabetes Complications 2023;37:108647.
PMID: 37952274